LexaGene’s CEO Provides Video Message on Company’s Progress and Announces Appointment of Dr. Shelley Rankin to Company’...
September 21 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to provide a video message from Dr. Jack Regan, LexaGene’s
Founder and CEO, on the Company’s progress towards commercial sales
and is also pleased to announce the appointment of Dr. Shelley
Rankin to LexaGene’s Scientific Advisory Board.
Dr. Jack Regan’s video message and MiQLab™ demonstration can be
viewed on the corporate website here:
https://lexagene.com/video-message-to-investors/
Regarding the appointment, Dr. Regan comments, “As we approach
sales, I’m very pleased to add Dr. Rankin to our Scientific
Advisory Board. She is an outspoken key opinion leader in
veterinary medicine and is constantly advocating for high quality
diagnostics for veterinarians in order to promote better animal
health and antibiotic stewardship. We look forward to working with
her to help meet the needs of veterinarians worldwide.”
Dr. Rankin is a Professor of Microbiology at the University of
Pennsylvania’s School of Veterinary Medicine (Penn Vet). She is the
Chief of Clinical Microbiology and Head of Diagnostic Services at
Penn Vet’s Ryan Hospital. She is a member of many scientific
societies, a past Chair of the American Society for Microbiology,
Animal Health Division (2011) and is currently Co-Chair of the
Subcommittee on Salmonella for the United States Animal Health
Association. She is an author of the International Society for
Companion Animal Infectious Diseases (ISCAID) Guidelines for
Antimicrobial Use to treat infections of the skin, urinary tract,
and respiratory tract. She has published 100 peer reviewed papers
and regularly speaks at international conferences. She has been
recognized as an Association of American Veterinary Medical
Colleges One Health Scholar and a Wharton Mack Institute Technology
Fellow.
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Director
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media ContactsNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024